Titan Pharmaceuticals, Inc. (Amex: TTP) has announced that the plaintiffs in the derivative and securities class action litigation brought against the Company have voluntarily dismissed their claims without prejudice. The securities class actions, intitially filed in the N.D. of Cal. last November, had alleged that Titan made false statements regarding the development of a new drug for treating schizophrenia.
Titan Pharmaceuticals Dismissed
Filed under Motion To Dismiss Monitor